Many of the widely used anticancer drugs induce dose-limiting peripheral neuropathies that undermine their therapeutic efficacy. Animal models of chemotherapy-induced painful peripheral neuropathy (CIPN) evoked by a variety of drug classes, including taxanes, vinca alkaloids, platinum-complexes, and proteasome-inhibitors, suggest that the common underlying mechanism in the development of these neuropathies is mitotoxicity in primary nerve sensory axons (PNSAs) arising from reduced mitochondrial bioenergetics [eg adenosine triphosphate (ATP) production deficits due to compromised respiratory complex I and II activity]. The causative mechanisms of this mitotoxicity remain poorly defined. However, peroxynitrite, an important pro-nociceptive agent, has been linked to mitotoxicity in several disease states and may also drive the mitotoxicity associated with CIPN. Our findings reveal that the development of mechano-hypersensitivity induced by paclitaxel, oxaliplatin, and bortezomib was prevented by administration of the peroxynitrite decomposition catalyst Mn(III) 5,10,15,20-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin (MnTE-2-PyP 5+ ) without interfering with their anti-tumor effects. Peak CIPN was associated with the nitration and inactivation of superoxide dismutase in the mitochondria, but not in the cytosol, as well as a significant decrease in ATP production within the PNSAs; all of these events were attenuated by MnTE-2-PyP 5+ . Our results provide continued support for the role of mitotoxicity in the development of CIPN across chemotherapeutic drug classes, and identify peroxynitrite as a key mediator in these processes, thereby providing the rationale towards development of ''peroxynitrite-targeted'' therapeutics for CIPN. Ó
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Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting complication of cancer chemotherapy and a frequent cause of discontinuation of what is otherwise successful therapy [49] . This chronic neuropathy is characterized by bilaterally symmetrical sensory symptoms (eg numbness, tingling, and pain) appearing in the feet, or in both the feet and hands [49] , and occurs with chemotherapeutics across drug classes with distinctly different anti-tumor mechanisms, such as taxanes (eg paclitaxel), platinum-complexes (eg oxaliplatin), and proteasome-inhibitors (eg bortezomib). Recent work in rats indicates a common pathophysiology for CIPN from these agents due to a long-lasting dysfunction in mitochondria of peripheral nerve sensory axons (PNSAs) [51, 53, 55, 56 ] that can be blocked by mitoprotective agents, such as acetyl-L-carnitine [53,56] and olesoxime [52] , and exacerbated by mitochondrial poisons [51] . These, and other, observations have led to a peripheral mitotoxicity hypothesis for CIPN, which posits that mitotoxicity within the PNSAs gives rise to persistent energy deficits leading to dysfunction of the sodium-potassium pump and a subsequent increase in abnormal spontaneous discharge in both A-and C-fibers, as well as degeneration of the sensory afferents' terminal arbors (intra-epidermal nerve fibers, the neuronal compartment with the highest energy requirement) [14, 51, [53] [54] [55] [56] . Increased spontaneous discharge of
